D
Terns Pharmaceuticals, Inc.
TERN
$3.18
-$0.27-7.83%
D
Sell
12/18/2023Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index and total return index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 12/18/2023 due to an increase in the volatility index and total return index.
E
Sell
12/1/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and total return index.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 12/1/2023 due to a decline in the volatility index and total return index.
D
Sell
11/15/2023Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 11/15/2023 due to an increase in the volatility index and valuation index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 11/15/2023 due to an increase in the volatility index and valuation index.
E
Sell
11/3/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 11/3/2023 due to a decline in the volatility index and growth index.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 11/3/2023 due to a decline in the volatility index and growth index.
D
Sell
10/16/2023Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 10/16/2023 due to an increase in the volatility index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 10/16/2023 due to an increase in the volatility index.
E
Sell
9/29/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 9/29/2023 due to a decline in the total return index and volatility index.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 9/29/2023 due to a decline in the total return index and volatility index.
D
Sell
9/14/2023Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 9/14/2023 due to an increase in the volatility index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 9/14/2023 due to an increase in the volatility index.
E
Sell
8/30/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 8/30/2023 due to a decline in the total return index and volatility index.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 8/30/2023 due to a decline in the total return index and volatility index.
D
Sell
8/11/2023Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 8/11/2023 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.3085 to -$0.2508, EBIT increased 12.41% from -$24.16M to -$21.16M, and operating cash flow increased 9.66% from -$14.38M to -$12.99M.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 8/11/2023 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.3085 to -$0.2508, EBIT increased 12.41% from -$24.16M to -$21.16M, and operating cash flow increased 9.66% from -$14.38M to -$12.99M.
E
Sell
8/9/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 8/9/2023 due to a decline in the total return index, volatility index and valuation index.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 8/9/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell
3/14/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to D- from D on 03/14/2023.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index and valuation index. EBIT declined 22.78% from -$14.08M to -$17.29M, and operating cash flow declined 20.37% from -$11.16M to -$13.44M.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to D- from D on 2/8/2023 due to a decline in the growth index and valuation index. EBIT declined 22.78% from -$14.08M to -$17.29M, and operating cash flow declined 20.37% from -$11.16M to -$13.44M.
D
Sell
9/1/2022Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D from D- on 9/1/2022 due to an increase in the volatility index and total return index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D from D- on 9/1/2022 due to an increase in the volatility index and total return index.
D
Sell
5/17/2022Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 5/17/2022 due to an increase in the growth index and solvency index. Earnings per share increased from -$0.5639 to -$0.545, the quick ratio increased from 24.34 to 24.54, and EBIT increased 0.38% from -$13.88M to -$13.83M.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 5/17/2022 due to an increase in the growth index and solvency index. Earnings per share increased from -$0.5639 to -$0.545, the quick ratio increased from 24.34 to 24.54, and EBIT increased 0.38% from -$13.88M to -$13.83M.
E
Sell
5/13/2022Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 05/13/2022.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 05/13/2022.
D
Sell
4/19/2022Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 4/19/2022 due to a large increase in the solvency index, volatility index and valuation index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E+ on 4/19/2022 due to a large increase in the solvency index, volatility index and valuation index.
E
Sell
3/25/2022Downgrade
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 3/25/2022 due to a substantial decline in the efficiency index, growth index and volatility index. Operating cash flow declined 32.01% from -$8.08M to -$10.67M, net income declined 20.39% from -$11.84M to -$14.25M, and earnings per share declined from -$0.4706 to -$0.5639.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E+ from D- on 3/25/2022 due to a substantial decline in the efficiency index, growth index and volatility index. Operating cash flow declined 32.01% from -$8.08M to -$10.67M, net income declined 20.39% from -$11.84M to -$14.25M, and earnings per share declined from -$0.4706 to -$0.5639.
D
Sell
11/3/2021Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E on 11/3/2021 due to a major increase in the growth index and valuation index. Earnings per share increased from -$0.8797 to -$0.4276, operating cash flow increased 38.81% from -$14.32M to -$8.76M, and EBIT increased 18.64% from -$13.3M to -$10.82M.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to D- from E on 11/3/2021 due to a major increase in the growth index and valuation index. Earnings per share increased from -$0.8797 to -$0.4276, operating cash flow increased 38.81% from -$14.32M to -$8.76M, and EBIT increased 18.64% from -$13.3M to -$10.82M.
E
Sell
8/2/2021Upgraded
Terns Pharmaceuticals, Inc. (TERN) was upgraded to E from E- on 8/2/2021 due to an increase in the valuation index.
Terns Pharmaceuticals, Inc. (TERN) was upgraded to E from E- on 8/2/2021 due to an increase in the valuation index.
E
Sell
5/18/2021None
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E- from U on 05/18/2021.
Terns Pharmaceuticals, Inc. (TERN) was downgraded to E- from U on 05/18/2021.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
